title: Differential degradation of motor deficits during gradual dopamine depletion with 6-hydroxydopamine in mice.
abstract: Parkinson's disease (PD) is a movement disorder whose cardinal motor symptoms arise due to the progressive loss of dopamine. Although this dopamine loss typically progresses slowly over time, currently there are very few animal models that enable incremental dopamine depletion over time within the same animal. This type of gradual dopamine depletion model would be useful in studies aimed at the prodromal phase of PD, when dopamine levels are pathologically low but motor symptoms have not yet presented. Utilizing the highly characterized neurotoxin 6-hydroxydopamine (6-OHDA), we have developed a paradigm to gradually deplete dopamine levels in the striatum over a user-defined time course - spanning weeks to months - in C57BL/6 mice. Dopamine depletions were achieved by administration of five low-dose injections (0.75μg) of 6-OHDA through an implanted intracranial bilateral cannula targeting the medial forebrain bundle. Levels of dopamine within the striatum declined linearly with successive injections, quantified using tyrosine hydroxylase immunostaining and high-performance liquid chromatography. Behavioral testing was carried out at each time point to study the onset and progression of motor impairments as a function of dopamine loss over time. We found that spontaneous locomotion, measured in an open field, was robust until ∼70% of striatal dopamine was lost. Beyond this point, additional dopamine loss caused a sharp decline in motor performance, reaching a final level comparable to that of acutely depleted mice. Similarly, although rearing behavior was more sensitive to dopamine loss and declined linearly as a function of dopamine levels, it eventually declined to levels similar to those seen in acutely depleted mice. In contrast, motor coordination, measured on a vertical pole task, was only moderately impaired in gradually depleted mice, despite severe impairments observed in acutely depleted mice. These results demonstrate the importance of the temporal profile of dopamine loss on the magnitude and progression of behavioral impairments. Our gradual depletion model thus establishes a new paradigm with which to study how circuits respond and adapt to dopamine loss over time, information which could uncover important cellular events during the prodromal phase of PD that ultimately impact the presentation or treatability of behavioral symptoms.
authors.affiliation: Department of Biological Sciences, Carnegie Mellon University, Pittsburgh, PA, USA; Center for the Neural Basis of Cognition, Carnegie Mellon University, Pittsburgh, PA, USA.
authors.forename: A M
authors.initials: AM
authors.lastname: Willard
authors.affiliation: Department of Biological Sciences, Carnegie Mellon University, Pittsburgh, PA, USA.
authors.forename: R S
authors.initials: RS
authors.lastname: Bouchard
authors.affiliation: Department of Biological Sciences, Carnegie Mellon University, Pittsburgh, PA, USA; Center for the Neural Basis of Cognition, Carnegie Mellon University, Pittsburgh, PA, USA. Electronic address: agittis@cmu.edu.
authors.forename: A H
authors.initials: AH
authors.lastname: Gittis
mesh_terms: D015102:3,4-Dihydroxyphenylacetic Acid / Q000378:metabolism; D018663:Adrenergic Agents / Q000633:toxicity*; D000818:Animals; D002851:Chromatography, High Pressure Liquid; D004195:Disease Models, Animal; D004298:Dopamine / Q000031:analogs & derivatives / Q000172:deficiency* / Q000378:metabolism; D004305:Dose-Response Relationship, Drug; D005106:Exploratory Behavior / Q000187:drug effects; D005260:Female; D006719:Homovanillic Acid / Q000378:metabolism; D008297:Male; D008474:Medial Forebrain Bundle / Q000187:drug effects / Q000502:physiology; D051379:Mice; D008810:Mice, Inbred C57BL; D009069:Movement Disorders / Q000209:etiology* / Q000378:metabolism*; D009638:Norepinephrine / Q000378:metabolism; D016627:Oxidopamine / Q000633:toxicity*; D011597:Psychomotor Performance / Q000187:drug effects; D012701:Serotonin / Q000378:metabolism; D013997:Time Factors
chemical_list: D018663:Adrenergic Agents; D015102:3,4-Dihydroxyphenylacetic Acid; D012701:Serotonin; D016627:Oxidopamine; C001746:3-methoxytyramine; D004298:Dopamine; D009638:Norepinephrine; D006719:Homovanillic Acid
keywords: Parkinson’s disease; basal ganglia; compensation; gradual depletion